
FSRH New Product Review: Kyleena® 19.5 mg Intrauterine Delivery System (January 2018, amended March 2019)
File size 309KB | Date: 04 March 2019
Date: 05 Mar 2019
Type: FSRH News and Information
Levosert (20mcg/24 hours) Intrauterine Delivery System (Levonorgesterel 52mg) is indicated for contraception and treatment of heavy menstrual bleeding. Licensed for 3 year use since its launch in the UK in early 2015, Levosert has now been approved in the UK for 5 years use.
This means that any existing women who have Levosert may keep their levosert IUS for 5 years from the date of the insertion as the product is exactly the same as it was previously when licenced for 3 or 4 years.
The updated Summary of Product Characteristics for Levosert notes that “Levosert should be removed after 5 years from the date of insertion”.
FSRH new product reviews for Levosert and Kyleena® has been updated to reflect the extended license period.
Read the product review below.